GlassScriptPhysician profile
Sangeetha Venugopal
NPI 1447651641
$11,146.71
in general payments reported to CMS, 2019-2025
8 companies · $5,522 in 2025
The $5,522 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $20.77 · 2023: $31.96 · 2024: $5,572 · 2025: $5,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,044 · Honoraria: $2,340 · Food and Beverage: $484 · Travel and Lodging: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,043.50 |
| Honoraria | $2,340.00 |
| Food and Beverage | $483.87 |
| Travel and Lodging | $258.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $3,187.77 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $2,889.48 | 2024-2025 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $2,372.00 | 2024 | |
| Sanofi US Services INC. | $1,904.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $687.50 | 2025 | |
| Celgene Corporation | $52.73 | 2022-2023 | Reblozyl |
| Astellas Pharma US INC | $27.64 | 2025 | Cresemba |
| Genzyme Corporation | $25.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sangeetha Venugopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.